Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12562322 | 0.87 | CYP19A1 (0.71) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL6821689 | 0.86 | CYP19A1 (0.56) | CYP19A1ALDH1A1SMN1; SMN2GRM5 | |
| SCHEMBL31528097 | 0.83 | CYP19A1 (1.00) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL2023479 | 0.83 | CYP19A1 (1.00) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL2029658 | 0.81 | CYP19A1 (0.63) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL2030959 | 0.79 | LMNA (0.75) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL676142 | 0.78 | LMNA (0.82) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL2194408 | 0.78 | CYP19A1 (0.66) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL30535283 | 0.78 | LMNA (0.82) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL4465817 | 0.77 | CYP19A1 (0.57) | CYP19A1ALDH1A1SMN1; SMN2LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477629-B1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | UNIV VANDERBILT (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| WO-2011035186-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | CYP19A1 4208/4885ALDH1A1 4706/4885SMN1; SMN2 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.